ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 3 pooled it
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Application of immunoPET imaging to enhance head and neck squamous cell carcinoma clinical management.Frontiers in oncology · 2025Pooled it
- Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2022Pooled it
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy.Journal for immunotherapy of cancer · 2026Article
- Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.Molecular imaging and biology · 2026Review
- Radiomic features of CECT and SUVmax of dual-tracer PET/CT reveal PD-L1 spatial heterogeneity in PDAC.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1.Molecules (Basel, Switzerland) · 2026Article
- A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.Journal of translational medicine · 2026Observational
- A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.Frontiers in immunology · 2026Article
- Mismatch Repair Gene Deficiency in Ovarian Cancer: A Clinicopathological Analysis of MLH1, PMS2, MSH2, and MSH6 Mutations Across Histological Subtypes.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Regulatory Mechanisms and Therapeutic Targeting of PD-L1 Trafficking and Stability in Cancer Immunotherapy.Cancers · 2025Review
- Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies.Frontiers in immunology · 2025Review
- The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy.Frontiers in immunology · 2025Review
- Therapeutic targeting of tumour-associated macrophage receptors.Immunotherapy advances · 2025Review
- The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors-Impact on Clinical Practice.Biomedicines · 2024Review
- TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3.Cancer immunology, immunotherapy : CII · 2024Article
- PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.Journal of molecular medicine (Berlin, Germany) · 2024Review
- CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer.BMC medical imaging · 2024Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Harriet M KlugerDepartment of Medicine, Yale University School of Medicine, New Haven, Connecticut. harriet.kluger@yale.edu.
Christopher R ZitoDepartment of Biology, School of Health and Natural Sciences, University of Saint Joseph, West Hartford, Connecticut.
Gabriela TurcuDepartment of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Marina K BaineDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Hongyi ZhangDepartment of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Adebowale AdeniranDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Mario SznolDepartment of Medicine, Yale University School of Medicine, New Haven, Connecticut.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Yuval KlugerDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Lieping ChenDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut.
Justine V CohenDepartment of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Lucia B JilaveanuDepartment of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Yale University · USCarol Davila University of Medicine and Pharmacy · ROUniversity of Saint Joseph · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI DAVID F STERN · 2006 to 2026
$43.9MYale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Shuangge Ma · 2015 to 2026
$31.1MInstitutional Career Development CoreKL2TR001862 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$12.2MYale University Clinical and Translational Science Award ProgramKL2TR000140 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$2.9MRenalase inhibition for treatment of unresectable melanomaR01CA216846 · NCI · YALE UNIVERSITY · PI DESIR, GARY V., KLUGER, HARRIET M. · 2017 to 2021
$2.4MInherent tropism and/or immune modulation in melanoma brain metastasisR01CA204002 · NCI · YALE UNIVERSITY · PI JILAVEANU, LUCIA BEATRICE · 2017 to 2021
$1.9MModels to Predict Prognosis and Benefit from Adjuvant Therapy in Renal Cell CarciR01CA158167 · NCI · YALE UNIVERSITY · PI KLUGER, HARRIET M. · 2011 to 2015
$1.8MA research and training program for junior clinicians in treating metastatic melaK24CA172123 · NCI · YALE UNIVERSITY · PI KLUGER, HARRIET M. · 2013 to 2017
$780kNCATS NIH HHS KL2 TR000140NCATS NIH HHS KL2 TR001862NCATS NIH HHS UL1 TR001863NCI NIH HHS K24 CA172123NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA121974NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA158167NCI NIH HHS R01 CA204002NCI NIH HHS R01 CA216846
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellFemaleGene Expression Regulation, NeoplasticHumansMaleMelanomaMiddle AgedNivolumabAntibodies, MonoclonalAntineoplastic AgentsB7-H1 AntigenBiomarkers, TumorCD274 protein, humanNivolumabPdcd1 protein, mouseProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.